Navigation Links
NeurogesX to Present at J.P. Morgan Health Care Conference

SAN MATEO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11-14, 2009 at the Westin St. Francis Hotel in San Francisco, California.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during a 25-minute breakout session immediately following the presentation, and to participate in one-on-one meetings with investors attending the conferences.

    Event:  28th Annual J.P. Morgan Healthcare Conference
    Date:   Thursday, January 14, 2009
    Time:   12:30 p.m. PT
    Place:  Westin St. Francis Hotel, San Francisco, CA (Elizabethan A/B)

The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at The webcasts will be archived for 90 days.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza® (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza®; the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: any regulatory approvals which are received may be limited to certain indications; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; difficulties or delays in the launch and commercialization of Qutenza; and the outcomes of any submissions to the FDA for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Sara Pellegrino (investors)
    (646) 536-7002

    Jason Rando (media)
    (646) 536-7025

SOURCE NeurogesX, Inc.



SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at Piper Jaffray Health Care Conference
2. NeurogesX Reports Third Quarter 2009 Results
3. NeurogesX to Present at Two November Conferences
4. NeurogesX to Present at UBS Global Life Sciences Conference
5. NeurogesX to Present at Upcoming Fall Conferences
6. NeurogesX Appoints New Board Director and Audit Committee Chairman
7. NeurogesX Reports Second Quarter 2009 Results
8. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
9. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
10. NeurogesX Added to Russell 3000 Index
11. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider ... , today announced that the company has set a new ... 391% quarter on quarter growth posted for Q3 of 2014 to ... and Mexico , with the establishment of an ... 2015. --> United Kingdom and ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):